GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forma Therapeutics Holdings Inc (NAS:FMTX) » Definitions » PS Ratio

Forma Therapeutics Holdings (Forma Therapeutics Holdings) PS Ratio : (As of Apr. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Forma Therapeutics Holdings PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Forma Therapeutics Holdings's share price is $20.01. Forma Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00. Hence, Forma Therapeutics Holdings's PS Ratio for today is .

The historical rank and industry rank for Forma Therapeutics Holdings's PS Ratio or its related term are showing as below:

During the past 4 years, Forma Therapeutics Holdings's highest PS Ratio was 181.67. The lowest was 0.00. And the median was 83.24.

FMTX's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.98
* Ranked among companies with meaningful PS Ratio only.

Forma Therapeutics Holdings's Revenue per Sharefor the three months ended in Jun. 2022 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00.

Warning Sign:

Forma Therapeutics Holdings Inc revenue per share has been in decline over the past 3 years.

Back to Basics: PS Ratio


Forma Therapeutics Holdings PS Ratio Historical Data

The historical data trend for Forma Therapeutics Holdings's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forma Therapeutics Holdings PS Ratio Chart

Forma Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21
PS Ratio
- - - -

Forma Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Forma Therapeutics Holdings's PS Ratio

For the Biotechnology subindustry, Forma Therapeutics Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forma Therapeutics Holdings's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forma Therapeutics Holdings's PS Ratio distribution charts can be found below:

* The bar in red indicates where Forma Therapeutics Holdings's PS Ratio falls into.



Forma Therapeutics Holdings PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Forma Therapeutics Holdings's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=20.01/0
=

Forma Therapeutics Holdings's Share Price of today is $20.01.
Forma Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Forma Therapeutics Holdings  (NAS:FMTX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Forma Therapeutics Holdings PS Ratio Related Terms

Thank you for viewing the detailed overview of Forma Therapeutics Holdings's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Forma Therapeutics Holdings (Forma Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
300 North Beacon Street, Suite 501, Watertown, MA, USA, 02472
Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others.
Executives
Agustin Melian officer: EVP, Research & Development C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Brian Andrew Lesser officer: SVP, Commercial Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET SUITE 501 WATERTOWN MA 02472
Mary E. Wadlinger officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Frank D. Lee director, officer: President and CEO C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
David N Cook officer: SVP, Chief Scientific Officer
Patrick F. Kelly officer: SVP, Chief Medical Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Todd Shegog officer: SVP, Chief Financial Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Arturo Md Molina director 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
John E Bishop officer: Chief Technology Officer 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Vickers Selwyn M Md director 600 NORTH 18TH STREET, BIRMINGHAM AL 35203
Thomas G Wiggans director
Frederick Wayne A.i. director 500 W MAIN ST., LOUISVILLE KY 40202
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Headlines

From GuruFocus

RA CAPITAL MANAGEMENT, L.P. Buys 2, Sells 3 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-18-2023